;

This content has been developed by Galderma and is intended for Healthcare Professionals Only.
Prescribing information for Relfydess™"▼ (relabotulinumtoxinA) and adverse event reporting information are available by clicking here

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Health professionals are asked to report any suspected adverse reactions. Prescribing information and adverse event reporting is available in the link at the bottom of the page.

Relfydess™ is indicated for the temporary improvement in the appearance of moderate-to-severe glabellar lines at maximum frown and moderate-to-severe lateral canthal lines at maximum smile alone or in combination, in adult patients under 65 years, when the severity of these lines has an important psychological impact on the patient.1

Step into the future of neuromodulation with Relfydess™

Pearl™ Technology: The breakthrough that makes Relfydess™ possible.

Relfydess™ is created using PEARL™ Technology, designed to optimise activity and purity for a highly active formulation containing only the essentials.*2,3

This gives fast and sustained results for glabellar lines and lateral canthal lines, giving patients a natural, revitalised look in a refined and well-tolerated formulation, with a low risk of immunogencity.†1,4-6

Advanced performance

See results for glabellar lines and lateral canthal lines from Day 1, through 6 months for up to 75% of patients.‡1,4-5

Baseline
Day 1
Month 1
Month 4
Baseline
Day 1
Month 1
Month 4

Before and after images for illustrative purposes only. Individual results may vary. All rights reserved. Permission sought to use patient’s images.

Pioneering simplicity

Simple volumetric dosing with this liquid formulation, eliminating the need for reconstitution.1-3

Injectors preferred Relfydess™ for 3 out of 4 treatments compared to standard powder neuromodulators requiring reconstitution.§7

High level of satisfaction

98% would return for treatment and would recommend Relfydess after 1 month, with up to 90% agreeing through 6 months.ǁ8,9

Shop now
* Relfydess™ is complexing protein-free and is free from human- or animal-derived components.1-3
† Relfydess™ treatment resulted in a low incidence of immunogenicity and no association of immunogenicity with any serious adverse events (AEs).6
‡ Kaplan-Meier analysis of diary card response for all ITT patients in the READY-1 and -2 studies for the first seven days following treatment. Time to onset calculated as the first diary day a patient noticed an improvement in appearance of their lines minus day of injection (Day 0). Median time to onset was two days.4,5
§ Based on the Injector Questionnaire completed for all ITT patients treated with Relfydess™ (n=99) in the RELAX Phase IIIb multicentreer, randomised, double-blind, placebo-controlled study evaluating aesthetic improvement and onset of effect after a single dose of Relfydess™ for the treatment of moderate-to-severe GLs (N=132) over 12 months. Injectors (N=9) agreed or strongly agreed with the statements ‘I prefer this ready to use product over other neuromodulator products that need to be reconstituted prior to use’, ‘I like that this ready to use product reduces preparation time and hassle’, ‘I felt this ready to use product increased the amount of time I can spend with my patient’, and ‘The ready to use product increases my confidence in dosing consistency’.7
ǁ Based on the FLTSQ completed by all ITT patients treated with Relfydess in the READY-1 and -2 studies. 98% (GLs, n=218) and 93% (LCLs, n=226) of patients at Month 1 and 90% (GLs, n=210) and 86% (LCLs, n=223) at Month 6 agreed or strongly agreed with the statement ‘I would have this treatment done again’. 98% (GLs) and 93% (LCLs) of patients at Month 1 and 90% (GLs) and 88% (LCLs) at Month 6 agreed or strongly agreed with the statement ‘I would recommend this treatment to others’.8,9
References: 1. Galderma. Relfydess™ Summary of Product Characteristics. 2024. 2. Sundberg ÅL, Ståhl U. Poster presented at: TOXINS 2021 Virtual Conference; January 16–17, 2021. 3. Do M, et al. Poster presented at: TOXINS 2022 Conference; New Orleans, US; July 27–30, 2022. 4. Galderma Laboratories. MA-47072. Clinical Study Report for Protocol 43QM1602: READY-1. Fort Worth, TX: 2021. 5. Galderma Laboratories. MA-47073. Clinical Study Report for Protocol 43QM1901: READY-2. Fort Worth, TX: 2021. 6. Galderma Laboratories. MA-47074. Clinical Study Report for Protocol 43QM1902: READY-3. Fort Worth, TX: 2022. 7. Galderma Laboratories. MA-59692. Clinical Study Report for Protocol 43QM2106: RELAX. Fort Worth, TX: 2023. 8. Galderma Laboratories. MA-47072. Clinical Study Report for Protocol 43QM1602: READY-1. Tables 14.02.11.04 and 14.02.12.02. Fort Worth, TX: 2021. 9. Galderma Laboratories. MA-47073. Clinical Study Report for Protocol 43QM1901: READY-2. Tables 14.2.12.4 and 14.2.13.2. Fort Worth, TX: 2021.
Prescribing information for Relfydess™▼ (relabotulinumtoxinA) and adverse event reporting information are available by clicking here
UKI-REL-2500058 | DOP April 2025

Adverse events should be reported. For the UK, Reporting forms and information can be found at 
www.mhra.gov.uk/yellowcard or search for Yellow Card in the
Google Play or Apple App Store.

For Ireland, Suspected adverse events can be reported via HPRA Pharmacovigilance,
Website: www.hpra.ie; Adverse events should also be reported
to Galderma (UK) Ltd, Email: medinfo.uk@galderma.com 
Tel: +44 (0) 300 3035674